Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:15 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 35,336 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: alone Clear all
Withdrawn Not applicable Interventional

Lung Irradiation for COVID-19 Pneumonia

NCT04393948
View directory record Official record
Conditions
SARS-CoV 2
Interventions
Phase 1, Phase 2
Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Nov 3, 2026, 5:15 AM EST
Completed Phase 2 Interventional Results available

Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers

NCT04491955
View directory record Official record
Conditions
Small Bowel Cancers, Colorectal Cancers
Interventions
CV301, MSB0011359C, N-803, NHS-IL12
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Nov 3, 2026, 5:15 AM EST
Completed Early Phase 1 Interventional

Online "Pain, Stress & Emotions" Class in Chronic Pain

NCT05014126
View directory record Official record
Conditions
Chronic Pain
Interventions
Pain, Stress and Emotions
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Nov 3, 2026, 5:15 AM EST
Completed No phase listed Observational

Single Balloon Enterosocpy Obscure Gastrointestinal Bleeding Bleed

NCT01625585
View directory record Official record
Conditions
Obscure Gastrointestinal Bleeding
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 16, 2013 · Synced Nov 3, 2026, 5:15 AM EST
Completed Not applicable Interventional Results available

Hearing Aid and Individuals With Cognitive Disorders

NCT04049643
View directory record Official record
Conditions
Presbycusis, Bilateral, Alzheimer Disease 2 Due to Apoe4 Isoform, Mild Cognitive Impairment
Interventions
Audiologist-based fitting, Service-only Fitting, Device-only fitting
Device
Lead sponsor
Yu-Hsiang Wu
Other
Eligibility
55 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Iowa City, Iowa • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Nov 3, 2026, 5:15 AM EST
Not yet recruiting Phase 3 Interventional

PO Methadone Ortho Outpatient

NCT06351215
View directory record Official record
Conditions
Arthroscopic Knee Repair, Arthroscopic Hip Repair
Interventions
Methadone group, Placebo
Drug
Lead sponsor
Keck School of Medicine of USC
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Nov 3, 2026, 5:15 AM EST
Terminated Not applicable Interventional Results available

Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3

NCT02586415
View directory record Official record
Conditions
Stroke, Acute, Cerebral Infarction
Interventions
Endovascular Thrombectomy, Trevo Retriever, Solitaire™ FR Revascularization Device, Penumbra thrombectomy system, Covidien MindFrame Capture Revascularization Device
Procedure · Device
Lead sponsor
Gregory W Albers
Other
Eligibility
18 Years to 90 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
40
States / cities
Birmingham, Alabama • Fresno, California • La Jolla, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Nov 3, 2026, 5:15 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

A Prospective Trial of an Endoscopic Quality Improvement Project

NCT02325635
View directory record Official record
Conditions
Colon Polyps
Interventions
Educational Training
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 13, 2015 · Synced Nov 3, 2026, 5:15 AM EST
Terminated Phase 2 Interventional

Study of RO6807952 in Patients With Diabetes Mellitus Type 2

NCT01516476
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Placebo, RO6807952, liraglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Nov 3, 2026, 5:15 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users

NCT06097676
View directory record Official record
Conditions
Abuse Potential
Interventions
Placebo, Alprazolam 2 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Nov 3, 2026, 5:15 AM EST
Completed Phase 2 Interventional Results available

Study of Tocilizumab to Treat Polymyalgia Rheumatica

NCT01396317
View directory record Official record
Conditions
Polymyalgia Rheumatica (PMR)
Interventions
Tocilizumab
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Nov 3, 2026, 5:15 AM EST
Not listed Not applicable Interventional

Prospective Packing Density With Target Coils I

NCT02292017
View directory record Official record
Conditions
Intracranial Aneurysm
Interventions
Embolization of intracranial aneurysm
Device
Lead sponsor
Tennessee Neurovascular Institute, LLC
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Nov 3, 2026, 5:15 AM EST
Recruiting Phase 4 Interventional

Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)

NCT07609940
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma (RRMM)
Interventions
Linvoseltamab, Tocilizumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Los Angeles, California • St. Petersburg, Florida • Baton Rouge, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 3, 2026, 5:15 AM EST
Completed Not applicable Interventional Results available

Theory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case Series

NCT02335450
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Motivational Interviewing, Wristband physical activity monitor
Behavioral · Device
Lead sponsor
Oakland University
Other
Eligibility
19 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Rochester, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Nov 3, 2026, 5:15 AM EST
Completed Not applicable Interventional

Screening, Motivational Assessment, Referral, and Treatment in Emergency Departments

NCT01207791
View directory record Official record
Conditions
Drug Abuse
Interventions
screening, assessment, referral, Brief intervention, booster sessions
Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
1,285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
7
States / cities
Miami, Florida • Boston, Massachusetts • Albuquerque, New Mexico + 4 more
Source: ClinicalTrials.gov public record
Updated May 24, 2013 · Synced Nov 3, 2026, 5:15 AM EST
Withdrawn Phase 2 Interventional

Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome

NCT04213274
View directory record Official record
Conditions
Schnitzler Syndrome, Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder)
Interventions
80 mg RPH-104, Placebo
Biological · Drug
Lead sponsor
R-Pharm Overseas, Inc.
Industry
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Denver, Colorado • Rochester, Minnesota • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Nov 3, 2026, 5:15 AM EST
Not listed No phase listed Observational

Prediction of Outcomes After Surgery for Unruptured Intracranial Aneurysms

NCT04819074
View directory record Official record
Conditions
Aneurysm, Brain
Interventions
Microsurgery
Procedure
Lead sponsor
University of Zurich
Other
Eligibility
18 Years and older
Enrollment
4,000 participants
Timeline
2021 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Nov 3, 2026, 5:15 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment

NCT05489614
View directory record Official record
Conditions
Renal Impairment
Interventions
Olpasiran
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
6
States / cities
Rialto, California • Yucaipa, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 3, 2026, 5:15 AM EST
Completed No phase listed Observational

Thoracolumbar Burst Fractures Study Comparing Surgical Versus Non-surgical Treatment

NCT02827214
View directory record Official record
Conditions
Thoracolumbar Burst Fracture
Interventions
Not listed
Lead sponsor
AO Innovation Translation Center
Other
Eligibility
18 Years to 65 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
San Diego, California • East Syracuse, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Nov 3, 2026, 5:15 AM EST
Completed Phase 2 Interventional Results available

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

NCT01083316
View directory record Official record
Conditions
Amyloidosis
Interventions
Bortezomib, Dexamethasone, Melphalan
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Nov 3, 2026, 5:15 AM EST
Completed Phase 3 Interventional Results available

Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)

NCT00856206
View directory record Official record
Conditions
Gout
Interventions
Rilonacept, Placebo
Biological · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
77
States / cities
Alabaster, Alabama • Mesa, Arizona • Burbank, California + 74 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Nov 3, 2026, 5:15 AM EST
Completed Phase 2 Interventional

Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy

NCT07501052
View directory record Official record
Conditions
Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, Diabetic Retinopathy
Interventions
SCD411 0.05mL (2mg)
Drug
Lead sponsor
Sam Chun Dang Pharm. Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
4
States / cities
Stuart, Florida • Winter Haven, Florida • Lemont, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Nov 3, 2026, 5:15 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Trigger Point Dry Needling With and Without Electrical Stimulation in Healthy Subjects

NCT07384247
View directory record Official record
Conditions
People With Identified Painful Trigger Points (Tp) Within the Soleus and Gastrocnemius Muscles Complex, Healthy Subjects or Volunteers
Interventions
Dry needling with electrical stimulation, Dry needling, Electrical stimulation, Sham
Procedure
Lead sponsor
University of Rhode Island
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Kingston, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Nov 3, 2026, 5:15 AM EST
Terminated Early Phase 1 Interventional

Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG

NCT05773326
View directory record Official record
Conditions
High Grade Glioma, Glioma, Glioma, Malignant, Glioblastoma
Interventions
Temsirolimus
Drug
Lead sponsor
Nader Sanai
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 3, 2026, 5:15 AM EST